GlassScriptPhysician profile
Izabella Gurau
NPI 1821034885
$193.58
in general payments reported to CMS, 2019-2025
4 companies · $57.20 in 2025
The $57.20 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.33 · 2020: $37.05 · 2021: $26.92 · 2022: $31.08 · 2025: $57.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79.55 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $37.12 | 2019-2020 | |
| Akebia Therapeutics INC | $19.71 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Izabella Gurau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.